Clinical Trial

A Phase Ib/II Study to Evaluate HLX43 Combined With HLX07 or Serplulimab in Patients With Advanced or Metastatic Colorectal Cancer

Name: A Phase Ib/II Study to Evaluate HLX43 Combined With HLX07 or Serplulimab in Patients With Advanced or Metastatic Colorectal Cancer — clinical trial record (NCT07358585)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

This study is a phase Ib/II study to evaluate the efficacy, safety and tolerance of HLX43 combined with HLX07 or Serplulimab in patients with advanced or metastatic colorectal cancer failed or intolerance to standard first-line therapy

Trial Details

NCT Number	NCT07358585
Lead Sponsor	Shanghai Henlius Biotech
Conditions	Colon Cancer Adenocarcinoma
Enrollment	126 participants
Start Date	2026-01-31
Primary Completion	2027-07-28 (estimated)
Study Completion	2028-08-23 (estimated)
Updated on ClinicalTrials.gov	2026-01-22